As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Climb Bio, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 33%. 13 filings are on record since September 18, 2025 (Schedule 13D/A, November 9, 2026).
Sell to companies like Climb Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 23,941,277 · Sole dispositive: 0 · Shared dispositive: 23,941,277 · SCHEDULE 13D/A, 2026-11-09
- · Reporting person: Fmr LLC · Sole voting: 8,615,203 · Shared voting: 0 · Sole dispositive: 8,615,432 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Deerfield Mgmt, L.P. · Sole voting: 0 · Shared voting: 3,070,000 · Sole dispositive: 0 · Shared dispositive: 3,070,000 · SCHEDULE 13G, 2026-10-28
- · Reporting person: BlackRock, Inc. · Sole voting: 2,831,010 · Shared voting: 0 · Sole dispositive: 2,895,165 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: MPM BioImpact LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
Climb Bio, Inc. has 13 Schedule 13D or 13G filings on record since 2025-09-18. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 33% | 23,941,277 | SCHEDULE 13D/A, 2026-11-09 | 2026-11-05 |
| Fmr LLC | 15% | 8,615,432 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Pontifax VI G.P. L.P. | 7.7% | 5,206,380 | SCHEDULE 13G, 2025-09-18 | 2024-06-27 |
| Deerfield Mgmt, L.P. | 5.25% | 3,070,000 | SCHEDULE 13G, 2026-10-28 | 2026-10-27 |
| BlackRock, Inc. | 5% | 2,895,165 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Ai Eti LLC | 0% | 0 | SCHEDULE 13D/A, 2025-10-16 | 2025-10-14 |
| MPM BioImpact LLC | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Climb Bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Climb Bio, Inc. and the records around it.
Climb Bio, Inc. elsewhere on the record
- Company profile and every filing May 2026
- Form D filing May 2026
- Who owns it
Companies that share a holder
- Pontifax VI G.P. L.P. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), Keros Therapeutics, Inc. (Oct 2025), LB Pharmaceuticals Inc (Sep 2025)
- MPM BioImpact LLC also filed stake reports on 4 other companies: Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026), Forte Biosciences, Inc. (May 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026), BiomX Inc. (Jun 2026)
Watch Climb Bio, Inc.
Get an email when Climb Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Climb Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Climb Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Climb Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 23,941,277 | 0 | 23,941,277 | SCHEDULE 13D/A, 2026-11-09 |
| Peter Kolchinsky | 0 | 23,941,277 | 0 | 23,941,277 | SCHEDULE 13D/A, 2026-11-09 |
| Rajeev Shah | 0 | 23,941,277 | 0 | 23,941,277 | SCHEDULE 13D/A, 2026-11-09 |
| RA Capital Healthcare Fund, L.P. | 0 | 17,693,174 | 0 | 17,693,174 | SCHEDULE 13D/A, 2026-11-09 |
| RA Capital Nexus Fund III, L.P. | 0 | 3,679,649 | 0 | 3,679,649 | SCHEDULE 13D/A, 2026-11-09 |
| Fmr LLC | 8,615,203 | 0 | 8,615,432 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 8,615,432 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Deerfield Mgmt, L.P. | 0 | 3,070,000 | 0 | 3,070,000 | SCHEDULE 13G, 2026-10-28 |
| Deerfield Management Company, L.P. | 0 | 3,070,000 | 0 | 3,070,000 | SCHEDULE 13G, 2026-10-28 |
| Deerfield Partners, L.P. | 0 | 3,070,000 | 0 | 3,070,000 | SCHEDULE 13G, 2026-10-28 |
| James E. Flynn | 0 | 3,070,000 | 0 | 3,070,000 | SCHEDULE 13G, 2026-10-28 |
| BlackRock, Inc. | 2,831,010 | 0 | 2,895,165 | 0 | SCHEDULE 13G, 2026-10-27 |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Climb Bio, Inc. by CUSIP 28658R106 and gives its principal executive office as 20 William Street, Suite G50, Wellesley Hills, MA 02481 (SCHEDULE 13D/A, 2026-11-09).
Source of funds (Item 3)
Item 3 of the Statement is hereby amended and supplemented as follows: On September 28, 2026 Andrew Levin exercised (i) 10,000 stock options (right to buy) at the exercise price of $3.46; (ii) 10,000 stock options (right to buy) at the exercise price of $3.00; (iii) 10,000 stock options (right to buy) at the exercise price of $7.89; and (iv) 40,000 stock options (right to buy) at the exercise price of $1.29. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the stock options for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr.RA Capital Management, L.P., SCHEDULE 13D/A, 2026-11-09
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | Pontifax VI G.P. L.P. | 7.7% | SCHEDULE 13G |
| 2025-10-07 | Ai Eti LLC | 5.66% | SCHEDULE 13D/A |
| 2025-10-16 | Ai Eti LLC | 0% | SCHEDULE 13D/A |
| 2025-12-15 | RA Capital Management, L.P. | 33% | SCHEDULE 13D/A |
| 2026-02-17 | MPM BioImpact LLC | 5.6% | SCHEDULE 13G |
| 2026-04-29 | RA Capital Management, L.P. | 33% | SCHEDULE 13D/A |
| 2026-07-07 | RA Capital Management, L.P. | 33% | SCHEDULE 13D/A |
| 2026-07-08 | Fmr LLC | 11.9% | SCHEDULE 13G |
| 2026-08-14 | MPM BioImpact LLC | 0% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5% | SCHEDULE 13G |
| 2026-10-28 | Deerfield Mgmt, L.P. | 5.25% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-11-09 | RA Capital Management, L.P. | 33% | SCHEDULE 13D/A |
Questions about who owns Climb Bio, Inc.
Who owns Climb Bio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Climb Bio, Inc.: RA Capital Management, L.P. (33%, Schedule 13D/A, filed 2026-11-09), Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05), Pontifax VI G.P. L.P. (7.7%, Schedule 13G, filed 2025-09-18), Deerfield Mgmt, L.P. (5.25%, Schedule 13G, filed 2026-10-28) and BlackRock, Inc. (5%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Climb Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Climb Bio, Inc. on this page are RA Capital Management, L.P. (33%), Fmr LLC (15%) and Pontifax VI G.P. L.P. (7.7%).
When did RA Capital Management, L.P. buy into Climb Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2025-12-15, reporting 33%; its latest, Schedule 13D/A filed 2026-11-09, reports 33%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Climb Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 1, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 4, 2026 | Form D, private offering | $110.08M sold | Form D page | Source |
| April 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Climb Bio, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Climb Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.